X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216187
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217328
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216187
https://www.biospace.com/article/phasebio-reversal-agent-continues-to-show-promise-in-phase-iii-/
https://www.fiercebiotech.com/biotech/phasebio-s-brilinta-reversal-agent-wins-midstage-test-as-biotech-awaits-key-interim-read
https://www.reuters.com/article/us-health-coronavirus-science/sobi-arthritis-drug-cuts-death-risk-heart-drugs-may-help-prevent-covid-19-blood-clots-idUSKBN2G61GD
https://www.fiercebiotech.com/biotech/phasebio-taps-a-manufacturing-partner-as-it-eyes-2022-filing-for-brilinta-reversing-drug
https://www.firstwordpharma.com/node/1775439?tsid=3
https://newsroom.heart.org/news/ticagrelor-was-not-superior-to-clopidogrel-to-reduce-heart-attack-risk-during-angioplasty
http://www.pharmafile.com/news/563426/astrazenecas-brilinta-combo-reduces-rate-disabling-stroke-or-death-stroke-patients-accor
https://www.fiercepharma.com/marketing/astrazeneca-blood-thinner-brilinta-new-fda-nod-hand-branches-out-into-stroke-patients
https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-approved-in-the-us-in-stroke.html
https://www.fiercepharma.com/marketing/astrazeneca-adds-covid-19-spin-to-both-heart-disease-awareness-and-brilinta-brand
http://www.pharmafile.com/news/553632/astrazeneca-s-brilinta-reduces-rate-stroke-and-death-patients-acute-ischaemic-stroke-or-
http://www.pharmatimes.com/news/az_unveils_detailed_data_from_thales_trial_1344983
https://www.astrazeneca.com/media-centre/press-releases/2020/brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in-patients-who-had-an-acute-ischemic-stroke-or-transient-ischemic-attack.html
http://www.pharmatimes.com/news/us_priority_review_for_az_brilintaaspirin_combination_1344667
https://www.nytimes.com/reuters/2020/06/01/world/europe/01reuters-astrazeneca-fda.html
https://finance.yahoo.com/news/development-u-fda-grants-breakthrough-105800667.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208596
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208508
http://www.pharmatimes.com/news/brilinta_found_to_reduce_bleeding_vs_dual_therapy_1332702
https://www.businesswire.com/news/home/20200330005412/en/BRILINTA-reduced-bleeding-dual-therapy-high-risk-coronary/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.fiercepharma.com/pharma/acc-astrazeneca-s-brilinta-taken-solo-reduced-bleeding-over-combo-therapy-new-data-shows
https://www.fiercepharma.com/pharma/astrazeneca-has-dumped-billions-into-brilinta-r-d-but-will-it-ever-pay-off
https://www.fiercebiotech.com/biotech/after-nash-flops-conatus-becomes-histogen-via-reverse-merger
https://endpts.com/astrazeneca-makes-case-for-use-of-blood-thinner-brilinta-in-stroke-patients/
http://www.pharmatimes.com/news/brilinta_hits_endpoint_in_late-stage_stroke_trial_1323581
https://www.fiercepharma.com/pharma/astrazeneca-s-brillinta-tops-aspirin-alone-reducing-cv-risks-prior-stroke-patients
http://www.pharmatimes.com/news/brilinta_reduces_cv_events_but_increases_bleeding_1300452
https://endpts.com/astrazenecas-clot-fighter-brilinta-shows-promise-in-diabetics-with-heart-disease-in-big-study/
https://www.statnews.com/pharmalot/2019/01/28/astrazeneca-medicare-out-of-pocket/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208531
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208575
https://www.fiercebiotech.com/biotech/idorsia-s-selatogrel-hits-goals-phase-2-cardiovascular-trials
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208567
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208599
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208575
https://www.biospace.com/article/phasebio-announces-pricing-of-initial-public-offering/
https://endpts.com/phasebio-details-dollars-in-astrazeneca-deal-as-it-rolls-out-a-plan-for-86m-plus-ipo/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208390
https://www.pharmacompass.com/pdf/news/brilinta-ticagrelor-astrazeneca-uk-et-al-v-hisun-pharmaceutical-1534741920.pdf
https://www.business-standard.com/article/companies/astrazeneca-drl-patent-case-fate-of-rs-2-35-bn-drug-to-be-decided-today-118073100179_1.html
Market Place
Share 
